Cases & Deals

Celgene asserts its POMALYST® patents against multiple generic companies under Hatch-Waxman Act

Clients Celgene Corporation

Jones Day is representing Celgene Corporation as a plaintiff to enforce its patents against multiple pharmaceutical companies including Teva Pharmaceuticals USA, Inc.; Apotex, Inc.; Hetero Labs Limited; Aurobindo Pharma Ltd.; Mylan Pharmaceuticals Inc.; Breckenridge Pharmaceutical, Inc.; and Natco Pharma Limited in several Hatch-Waxman litigation matters involving their proposed generic versions of POMALYST®, which is prescribed for treating multiple myeloma.

Celgene Corporation v. Hetero Labs Limited, et al., Nos. 2-17-cv-03387, 2-18-cv-14111 (D.N.J.); Celgene Corporation v. Teva Pharmaceuticals USA Inc., et al., No. 2-18-cv-14366 (D.N.J.); Celgene Corporation v. Breckenridge Pharmaceutical, Inc., et al., No. 2-18-cv-14715 (D.N.J.); Celgene Corporation v. Mylan Pharmaceuticals Inc. et al., No. 2-18-cv-16035 (D.N.J.); Celgene Corporation v. Apotex, Inc., No. 2-18-cv-16395 (D.N.J.); Celgene Corporation v. Aurobindo Pharma Limited, et al., No. 2-19-cv-00143 (D.N.J.)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.